Kevin M. Slawin, Chief Technology Officer at BELLICUM PHARMACEUTICALS, INC (BLCM), sold 103,000 shares at $19.27 ($2.0M) on 2016-08-15, disclosed to the SEC on 2016-08-17.
Open-market sale of $2.0M BLCM by Chief Technology Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.27 | 34,127 | $658K | 33.1% |
| 2 | $19.27 | 34,127 | $658K | 33.1% |
| 3 | $19.27 | 29,000 | $559K | 28.1% |
| 4 | $20.01 | 1,873 | $37K | 1.9% |
| 5 | $20.01 | 1,873 | $37K | 1.9% |
| 6 | $20.01 | 2,000 |
| $40K |
| 2.0% |
| Total | $19.31 avg | 103,000 | $2.0M | 100% |
| Filing → |
| BLCM | SELL | 2016-09-23 | $936K | — | Filing → |
| BLCM | SELL | 2016-09-20 | $92K | — | Filing → |
| BLCM | SELL | 2016-07-29 | $225K | — | Filing → |